Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05456256 · ClinicalTrials.gov registry record · Phase 2
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
A Phase 2 study of Carcinoma, Non-Small Cell Lung and Adenocarcinoma of Lung, sponsored by Lantern Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 16
- Study locations
NCT05456256: Recruiting Phase 2 study of Carcinoma, Non-Small Cell Lung and Adenocarcinoma of Lung, sponsored by Lantern Pharma.
NCT05456256 is a Phase 2 study of Carcinoma, Non-Small Cell Lung and Adenocarcinoma of Lung that is actively recruiting participants, run by Lantern Pharma. The registered enrollment target is 90 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (72% lower). The trial reports 16 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05456256, a Phase 2 study of Carcinoma, Non-Small Cell Lung and Adenocarcinoma of Lung, is actively recruiting participants, sponsored by Lantern Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 16
- Study locations
Study Summary
The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker patient population. The primary objectives of this study are to determine progression-free survival (PFS) and overall survival (OS) in the study-defined patient population when LP-300 is co-administered with the standard of care chemotherapy drugs carboplatin and pemetrexed compared to carboplatin and pemetrexed alone. This has been designed as a multicenter, open label, phase II trial with 90 patients to be enrolled in the United States.
Primary Outcome
Number of days or months from the date of randomization to the earliest of the documented disease progression based on the Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 criteria
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG LP-300
Study Locations (16)
Other
- Chi Mei Medical Center - Tainan
- National Cheng Kung University Hospital - Tainan
- Taipei Veterans General Hospital - Taipei
- TriService General Hospital-Neihu Main Facility - Taipei
- National Taiwan University Hospital Hsin-Chu Branch - Taoyuan District
California
- Precision NextGen Oncology and Research Center - Beverly Hills
- Los Angeles Cancer Network - Fountain Valley
- Cancer and Blood Specialists Clinic - Los Alamitos
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Texas
- UT Southwestern Medical Center - Dallas
Virginia
- Inova Fairfax Hospital - Fairfax
Hokkaido
- Hokkaido Cancer Center - Sapporo
Kanagawa
- Kanagawa Cancer Center Hospital - Yokohama
Miyagi
- Tohoku University Hospital - Sendai
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What NCT05456256 shows while recruiting
NCT05456256 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (72% lower).
The record links to 2 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT05456256 lists 16 locations in 10 states (Other, California, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT05456256 about?
NCT05456256 is a clinical study titled "A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma". The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker patient population. The primary objectives of this study are to determine progression-free survival (PFS) and overall survival (OS) in the study-defined p...
What is the current status of trial NCT05456256?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2023-03-01. Estimated completion is 2026-06.
What conditions does trial NCT05456256 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Adenocarcinoma of Lung.
What interventions are being tested in trial NCT05456256?
The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG), LP-300 (DRUG).
Who is sponsoring clinical trial NCT05456256?
This trial is sponsored by Lantern Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05456256 being conducted?
This trial has 16 study locations across California, Pennsylvania, Texas, Virginia, Hokkaido. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05456256's enrollment target sits among peer trials
90 76th of 130 higher than 55 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
RECRUITING · Phase 2
-
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
RECRUITING · Phase 2
-
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
RECRUITING · Phase 2
-
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
RECRUITING · Phase 2
-
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI